Your selection
Research, Innovation, Patient care, Education / 18.06.2025
Students from Freie Universität Berlin visited the Campus Berlin-Buch
Visiting the Campus Berlin-Buch: Master's students in Biology at Freie Universität Berlin learned about career opportunities and start-ups at the BiotechPark Berlin-Buch on June 11, 2025.
During a tour of the campus with Campus Manager Dr. Ulrich Scheller, they were first given an overview of the closely cooperating research institutions and biotech companies as well as the location of future innovation Berlin-Buch, whose profile focuses on biomedicine and health.
Dr. Uwe Lohmeier, Head of the Berlin BioScience Academy, and Trendelina Rrustemi, Senior Scientist at Alithea Biotechnology GmbH, gave an insight into their career paths at the Career Panel Talk in the BerlinBioCube start-up center building. Dr. Lohmeier explained the development opportunities offered by the Berlin BioScience Academy (BBA).
Trendelin Rrustemi presented her start-up Alithea Biotechnology GmbH. It offers pioneering HLA peptide characterization with innovative immunopeptidomics, highly sensitive mass spectrometry and applied AI.
The students were then given an insight into the start-ups CUTANEON - Skin & Hair Innovations GmbH, Cultimate Foods GmbH and FyoniBio GmbH
The BiotechPark on the Campus Berlin-Buch is one of the leading technology parks in Germany. Buch has been renowned for its clinics and cutting-edge research for around 100 years and is now one of the largest biomedical locations in Germany.
The Berlin BioScience Academy (BBA), formerly known as "Gläsernes Labor Akademie (GLA)", supports young scientists throughout Germany in their professional orientation and entry into the pharmaceutical and biotechnology industry.
www.glaesernes-labor-akademie.de
Overview News
News Buch Berlin
A fresh take on proteomics
Start-up company Absea Biotechnology GmbH is developing new proteomics technologies. An interview with Dr. Philip Lössl, Senior VP Science and Business Development
more ...A double-pronged attack on malignant B cells
Multiple myeloma, a cancer of the bone marrow, remains difficult to treat despite modern CAR T cell therapies. In “Molecular Therapy,” a team led by Armin Rehm presents an improved immunotherapy that ...
more ...A new opportunity for Berlin
The Einstein Center for Early Disease Interception has been funded with six million euros. In an interview, Nikolaus Rajewsky and Leif Erik Sander, both spokespeople of the center, explain why new tec...
more ...Events Buch Berlin
26.01.2026, 16:00
Einfach Wissen: Desinformation als Strategie? Neue Spielarten politischen Handelns im digitalen Raum
Im Auftakt der neuen Reihe "Einfach Wissen" von rbb24 und der Technologiestiftung Berlin zeigt Prof. Dr. Jeanette Hofmann, welche Rolle Falschinformationen bei denjenigen spielen, die sich von der Dem...
more ...28.01.2026, 16:00
Labor trifft Lehrer*in: Wie Hirnorganoide helfen, Therapien für Neuroentwicklungs- krankheiten zu entwickeln
Vortrag von Jakob Metzger, Max Delbrück Center: Seltene genetische Veränderungen können die Entwicklung des menschlichen Gehirns tiefgreifend beeinflussen und neurologische Erkrankungen verursachen – ...
more ...28.01.2026, 17:00
"Musik trifft Wissenschaft" Bucher Campus-Klassikkonzert
mit den Pianisten Tabea und Daniel Streicher, die Werke von Ravel, Bartok, Bach u.a. spielen
more ...
